Regulus Therapeutics (stock symbol: RGLS) Logo in transparent PNG format

Regulus Therapeutics Logo large

Regulus Therapeutics Logo icon format

About Regulus Therapeutics

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

  • Website domain: regulusrx.com
  • Employees: 25
  • Marketcap: $24.87 Million USD

Page last updated on:

December 7th, 2020

Categories: